Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Medical Oncology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1758834009343454v1
1/2/69    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dorff, T. B.
Right arrow Articles by Thompson, I. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Tanya B. Dorff

University of Michigan, Division of Hematology/ Oncology, 1500 E. Medical Center Dr., 7314 CCGC, Ann Arbor, MI 48109-0946, USA, mahahuss{at}umich.edu, University of Southern California, Los Angeles, CA, USA

Cathy M. Tangen

Southwest Oncology Group Statistical Center, Seattle, WA, USA

E. David Crawford

University of Colorado, Denver, CO, USA

Daniel P. Petrylak

Columbia University, New York, NY, USA

Celestia S. Higano

University of Washington, Seattle, WA, USA

Derek Raghavan

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

David I. Quinn

University of Southern California, Los Angeles, CA, USA

Nicholas J. Vogelzang

Nevada Cancer Institute, Las Vegas, NV, USA

Ian M. Thompson

University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

Key Words: advanced prostate cancer • chemotherapy • androgen deprivation • clinical trials

This version was published on September 1, 2009

Therapeutic Advances in Medical Oncology, Vol. 1, No. 2, 69-77 (2009)
DOI: 10.1177/1758834009343454
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?